Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I dont think there is much correlation until these bobos manage to accomplish something that will make money. Sure wouldnt be a surprise if today was precursor to some really good news!
Pr wasnt necessary. Dont get it. Not desperation though just something that should be ignored for now like the stock price
Dont cry, buy
You will be back. Good luck!
Exactly! See, your timing is impeccable. Probably why you have so many Marks. This stock is beaten down hard! bMSN too which owns 56% of regen
Its nothing. Any significant news should make it move nicely. Just waiting... Its a comin dammit!
Sure but if therapies could be ecfective on ebola thpe of sickness then its good to look at it and doesnt hurt to at least consider the potential
What goes down must come up!!
GREEN BABY!!! Haha!!!
What are you thinking Inventor? First week of November? 2nd week? Pps is a shame but great to avg down eh?
I expect news every week! Lol
Patel is like the the Yanks bringing mariano rivera out of the bullpen in the 9 th inning to finish off the job. Great things about to happen for patient longs. BMSN!
Good thing chart wont matter when FDA green lights us early November. Expect dda go ahead and dcellvax ind around same time
With a true catalyst (fda green light) and this tiny float, we will move very quickly and we can all start arguing again about where its headed ! But, we will argue whether it will be staying above or below a dollar. Imo
I just bought more. These are sale prices!
When stem cells that "kill cancer" are injected into our bodies i will be happy knowing the FDA took their time and required additional safety data before using on humans. I will also be forever grateful that these doctors pushed and scrambled to get the treatments on the market.
And i will be out of my mind when rgbp is traded on NYSE at 50-100 per share!!!
IS is a very good word! Patel came just before clinicaltrial IS initiated!
That 14 is a hot spot. Lookin GOOD! Bmsn
And buy more when the plan works because it will be short lived
Wrong this one isnt toast! Bmsn owns more than half of rgbp and they will rise together. This one soooo low a pps that it would be foolish to not throw money at it even if you are also buying regen. Dont u think u could earn a much higher percent gain on bmsn from this level? I do imo
Sorry Goat.. Good call. U said it yesterday! The days have been mooshing together lately with the boredom
Easy Goat you said news "tomorrow "
Future very bright. Kills can er cells in humans, no toxicity, kills cells that cause relapses
AWESOME pr!!
GREAT PR!!!
Cmon koos my account looks like the Treasury balance sheet
Fda hand holding and guidance for hema should shorten app process for dcellvax
When these cheapies reload and the fDA finally blesses us we will all be eating ice cream and drinking lemonade!
Interesting article. Promising timeline. So we arent crazy
Its so messy. Typical koos. He is so overdue to get something right i cant help thinking he will
Mix up a strong one and have a great weekend! Monday we another week closer to fda approval
Potential future value. But i agree its pretty amazing thats why im not selling. Gracias
Thanks J i just made it up and i know most of it doesnt make sense but what the hell i guess my posts are alot like a koos pr!
I dont understand the initial strength of regen when it was released without news ??? It should be $.15 right now. Company hasnt accomplished anything material(yet). I think they will tho and am holding my millions until that day.
Still. I dont believe it was self-sabotage. Id say it was the truth. and where we thought we were is not where we are and where we hope to be is a little further away than where we are now. And the market is telling us that by pps
Look.. Market doesnt like the update or the current situation. Period. Pps tells the whole story. Speculating on reasons til we r blue wont change anything.
When the market feels its fairly valued the pps will stabilize. If you are short term i say bail, if u believe in science and future then its time to sit tight again until these guys work things out. Thats what im doing. Glta imho
Eh.. Weve been lower than this before.
PR: very close! All approved except final safety.
Regen BioPharma Provides Update on HemaXellerate IND Progress After Conference Call With FDA
Regen to Conduct GLP Safety Study to Provide Additional Supporting Data to FDA as the Company Moves Forward With HemaXellerate Development
Marketwired Bio-Matrix Scientific Group, Inc. 58 minutes ago
SAN DIEGO, CA--(Marketwired - Sep 10, 2014) - Regen BioPharma Inc. (OTCBB: RGBP) announced today the outcome of a telephonic meeting with the FDA regarding IND #15376 for use of HemaXellerate in the treatment of aplastic anemia. The subject of this meeting with FDA cell therapy experts was the Company's existing experimental data and the requirement for additional safety data with regard to the IND application.
Regen had been previously notified by the FDA that it had cleared the clinical trial design, scientific rational and manufacturing components of its IND application. The Company was informed that before it is cleared to initiate a clinical trial, it must submit additional safety data from experiments conducted in a GLP certified laboratory. One of the reasons the FDA requested additional safety study data centers around the fact that HemaXellerate is a cell based drug.
"We are grateful for the examiners at the FDA to have taken the time to walk us through their thinking and explaining to us what they believe will add the greatest level of safety to our HemaXellerate product. By closely working with the FDA now, we believe the path for future trials, including other disease indications will be much smoother," said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma Inc.
"Our first concern in product development is safety and the well being of patients participating in our planned future clinical trial. By leveraging the experience of the FDA and their cell therapy experts, we are confident that we will develop a strong product that will help aplastic anemia patients, which are currently without viable treatment options," said David Koos Chairman and CEO of Regen BioPharma Inc.
HemaXellerate is a personalized stem cell therapy that stimulates production of blood cells from the bone marrow of patients. Regen is planning to utilize HemaXellerate to treat patients with aplastic anemia, a condition associated with reduced ability of the bone marrow to make blood. The Company's CEO also stated, "If successful, the Company may expand into other conditions such as poor blood production associated with chemotherapy which is a potential multibillion dollar per year market."
About Regen BioPharma Inc.:
Regen BioPharma Inc., (OTCBB: RGBP) a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
Phone: 619-702-1404
Fax: 619.330.2328
www.regenbiopharma.com
I will take two. Maybe a martini for you? RGBP! Good day
Dear BMAK, welcome to Regen, launching pad for cancer destroying stem cell science